<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>TETRACAINE- tetracaine hydrochloride injection </strong><br>Akorn, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>TETRACAINE 1%
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Tetracaine HCl Injection, USP</span><br><span class="Bold">for Prolonged Spinal Anesthesia</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>Description
</h1>
<p class="First">Tetracaine hydrochloride is 2-(Dimethylamino)ethyl p-(butylamino)benzoate monohydrochloride. It is a white crystalline, odorless powder that is readily soluble in water, physiologic saline solution, and dextrose solution. It has the following structural formula:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b29124f7-c238-4961-b810-f4e7fabe4bb1&amp;name=tetracaine-01.jpg">
</div>
<p>Tetracaine hydrochloride is a local anesthetic of the ester-linkage type, related to procaine.
</p>
<p><span class="Bold">1% Solution:</span> A sterile, isotonic, isobaric solution.
</p>
<p><span class="Bold">Each mL contains:</span></p>
<p><span class="Bold">Active:</span> 10 mg Tetracaine Hydrochloride
</p>
<p><span class="Bold">Inactives:</span> 7.5 mg Sodium Chloride, Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (3.2 to 6.0) and Water for Injection, USP.
</p>
<p>Nitrogen gas has been used to displace the air in the ampules.
</p>
<p>This formulation does not contain preservatives.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Parenteral administration of tetracaine hydrochloride stabilizes the neuronal membrane and prevents initiation and transmission of nerve impulses thereby effecting local anesthesia.
</p>
<p>The onset of action is rapid, and the duration is prolonged (up to two or three hours or longer of surgical anesthesia).
</p>
<p>Tetracaine hydrochloride is detoxified by plasma esterases to aminobenzoic acid and diethylaminoethanol.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s6"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Tetracaine hydrochloride is indicated for the production of spinal anesthesia for procedures requiring two to three hours.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Spinal anesthesia with tetracaine hydrochloride is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tetracaine hydrochloride or to drugs of a similar chemical configuration (ester-type local anesthetics), or aminobenzoic acid or its derivatives; and in patients for whom spinal anesthesia as a technique is contraindicated.
</p>
<p>The decision as to whether or not spinal anesthesia should be used for an individual patient should be made by the physician after weighing the advantages with the risks and possible complications. Contraindications to spinal anesthesia as a technique can be found in standard reference texts, and usually include generalized <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the site of injection, certain diseases of the cerebrospinal system, uncontrolled <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, etc.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First"><span class="Bold">RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE IMMEDIATELY AVAILABLE WHENEVER ANY LOCAL ANESTHETIC DRUG IS USED.</span></p>
<p>Large doses of local anesthetics should not be used in patients with heartblock.
</p>
<p>Reactions resulting in fatality have occurred on rare occasions with the use of local anesthetics, even in the absence of a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s9"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<p class="First">The safety and effectiveness of any spinal anesthetic depend upon proper dosage, correct technique, adequate precautions, and readiness for emergencies. The lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious systemic side effects. Tolerance varies with the status of the patient; debilitated, elderly patients or acutely ill patients should be given reduced doses commensurate with their weight, age, and physical status. Reduced doses are also indicated for obstetric patients and those with increased intra-abdominal pressure.
</p>
<p>Caution should be used in administering tetracaine hydrochloride to patients with abnormal or reduced levels of plasma esterases.
</p>
<p>Blood pressure should be frequently monitored during spinal anesthesia and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> immediately corrected.
</p>
<p>Spinal anesthetics should be used with caution in patients with severe disturbances of cardiac rhythm, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, and heartblock.
</p>
<div class="Section" data-sectionCode="34073-7">
<a name="s10"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold Italics">Drug Interactions:</span> Tetracaine hydrochloride should not be used if the patient is being treated with a sulfonamide because aminobenzoic acid inhibits the action of sulfonamides.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s11"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold Italics">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> There have been no long-term animal studies to evaluate carcinogenic potential and reproduction studies in animals. There is no evidence from human data that tetracaine hydrochloride may be carcinogenic or that it impairs fertility.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s12"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold Italics">Pregnancy Category C:</span> There have been no animal reproduction studies conducted with tetracaine hydrochloride. It is not known whether tetracaine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Tetracaine hydrochloride should be given to a pregnant woman only if clearly needed and the potential benefits outweigh the risk.
</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s13"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold Italics">Labor and Delivery:</span> Vasopressor agents administered for the treatment of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> resulting from spinal anesthesia may result in severe persistent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and/or rupture of cerebral blood vessels if oxytocic drugs have also been administered; therefore, vasopressors should be used with extreme caution in the presence of oxytocic drugs.
</p>
<p>Tetracaine hydrochloride has a recognized use during labor and delivery; the effect of the drug on duration of labor, incidence of forceps delivery, status of the newborn, and later growth and development of the child have not been studied.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s14"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold Italics">Nursing Mothers:</span> It is not known whether tetracaine hydrochloride is excreted in human milk; however, it is rapidly metabolized following absorption into the plasma. Because many drugs are excreted in human milk, caution should be exercised when tetracaine hydrochloride is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s15"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Use:</span> Safety and effectiveness of tetracaine hydrochloride in pediatric patients have not been established.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s16"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Systemic adverse reactions to tetracaine hydrochloride are characteristic of those associated with other local anesthetics and can involve the central nervous system and the cardiovascular system. Systemic reactions usually result from high plasma levels due to excessive dosage, rapid adsorption, or inadvertent intravascular injection.
</p>
<p>A small number of reactions to tetracaine hydrochloride may result from <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, idiosyncrasy or diminished tolerance to normal dosage.
</p>
<p><span class="Italics">Central nervous system</span> effects are characterized by excitation or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. The first manifestation may be <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, followed by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and possibly respiratory and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Since <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> may be transient or absent, the first manifestation may be <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, sometimes merging into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and respiratory and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Other central nervous system effects may be <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, constriction of the pupils, or <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.
</p>
<p><span class="Italics">Cardiovascular system</span> reactions include <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium, blood pressure changes (usually <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>), and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.
</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span></span>, which may be due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, idiosyncrasy, or diminished tolerance, are characterized by cutaneous lesions (eg. <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and other manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>. Detection of sensitivity by skin testing is of limited value. Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have rarely occurred and are not usually dose-related.
</p>
<p><span class="Bold Italics">Reactions Associated with Spinal Anesthesia Techniques:
</span><span class="Italics">Central Nervous System:</span> post-spinal <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningismus</span>, <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>, palsies, or spinal <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">nerve paralysis</span>. <span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> due to vasomotor <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and pooling of the blood in the venous bed. <span class="Italics">Respiratory:</span> respiratory impairment or <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> due to the level of anesthesia extending to the upper thoracic and cervical segments. <span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold Italics">Treatment of Reactions:</span> Toxic effects of local anesthetics require symptomatic treatment; there is no specific cure. <span class="Bold">The most important measure is oxygenation of the patient by maintaining an airway and supporting ventilation.</span> Supportive treatment of the cardiovascular system includes intravenous fluids and, when appropriate, vasopressors (preferably those that stimulate the myocardium). <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> are usually controlled with adequate oxygenation alone but intravenous administration in small increments of a barbiturate (preferably an ultrashort-acting barbiturate such as thiopental and thiamylal), or diazepam can be utilized. Intravenous barbiturates or anticonvulsant agents should only be administered by those familiar with their use and only if ventilation and oxygenation have first been assured. In spinal anesthesia, sympathetic blockade also occurs as a pharmacological action, resulting in peripheral vasodilation and often <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The extent of the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> will usually depend on the number of dermatomes blocked. The blood pressure should therefore be monitored in the early phases of anesthesia. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, it is readily controlled by vasoconstrictors administered either by the intramuscular or the intravenous route, the dosage of which would depend on the severity of the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and the response to treatment.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s18"></a><a name="section-9"></a><p></p>
<h1>Dosage and Administration
</h1>
<p class="First">As with all anesthetics, the dosage varies and depends upon the area to be anesthetized, the number of neuronal segments to be blocked, individual tolerance, and the technique of anesthesia. The lowest dosage needed to provide effective anesthesia should be administered. For specific techniques and procedures, refer to standard textbooks.
</p>
<a name="t300"></a><table width="100%">
<caption><span>Suggested Dosage for Spinal Anesthesia Using 1% Tetracaine HCl Injection, USP
</span></caption>
<col align="left" width="24.475%">
<col align="left" width="23.525%">
<col align="left" width="26.000%">
<col align="left" width="26.000%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote">* For vaginal delivery (saddle block), from 2 mg to 5 mg in dextrose.
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">†</span> Doses exceeding 15 mg are rarely required and should be used only in exceptional cases. Inject solution at rate of about 1 mL per 5 seconds.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top">Extent of
</td>
<td align="center" valign="top">Dose of solution
</td>
<td align="center" valign="top">Volume of spinal fluid
</td>
<td align="center" valign="top">Site of injection
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Anesthesia
</td>
<td class="Botrule" align="center" valign="top">(mL)
</td>
<td class="Botrule" align="center" valign="top">(mL)
</td>
<td class="Botrule" align="center" valign="top">(lumbar interspace)
</td>
</tr>
<tr>
<td align="left" valign="top">Perineum
</td>
<td align="center" valign="top">0.5 (= 5 mg)*
</td>
<td align="center" valign="top">0.5
</td>
<td align="center" valign="top">4<span class="Sup">th</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Perineum and
</td>
<td align="center" valign="top">1.0 (= 10 mg)
</td>
<td align="center" valign="top">1.0
</td>
<td align="center" valign="top">3<span class="Sup">rd</span> or 4<span class="Sup">th</span>
</td>
</tr>
<tr>
<td align="left" valign="top">lower extremities
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Up to costal
</td>
<td align="center" valign="top">1.5 to 2.0
</td>
<td align="center" valign="top">1.5 to 2.0
</td>
<td align="center" valign="top">2<span class="Sup">nd</span>, 3<span class="Sup">rd</span>, or 4<span class="Sup">th</span>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="2" valign="top">margin(= 15 mg to 20 mg)<span class="Sup">†</span>
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
</tbody>
</table>
<p>The extent and degree of spinal anesthesia depend upon dosage, specific gravity of the anesthetic solution, volume of solution used, force of the injection, level of puncture, position of the patient during and immediately after injection, etc.
</p>
<p>When spinal fluid is added to 1% tetracaine hydrochloride injection, some turbidity results, the degree depending on the pH of the spinal fluid, the temperature of the solution during mixing, as well as the amount of drug and diluent employed. Liberation of base (which is completed within the spinal canal) is held to be essential for satisfactory results with any spinal anesthetic.
</p>
<p>The specific gravity of spinal fluid at 25°C/25°C varies under normal conditions from 1.0063 to 1.0075. The 1% concentration in saline solution has a specific gravity of 1.0060 to 1.0074 at 25°C/25°C.
</p>
<p>A hyperbaric solution may be prepared by mixing equal volumes of the 1% solution and Dextrose Solution 10%.
</p>
<p>Examine ampules carefully before use. Do not use solution if crystals, cloudiness, or discoloration is observed.
</p>
<p><span class="Bold">This formulation of tetracaine hydrochloride does not contain antimicrobial or bacteriostatic agents; therefore, unused portions should be discarded.</span></p>
<p><span class="Bold">Sterilization of Ampules</span></p>
<p>The tetracaine hydrochloride injection is sterile within an undamaged ampule. To destroy bacteria on the exterior of ampules use heat sterilization (autoclaving) before opening. Immersion in antiseptic solution is not recommended.
</p>
<p><span class="Bold">Autoclave at 15-pounds pressure, at 121°C (250°F), for 15 minutes.</span></p>
<p><span class="Bold">Autoclaving increases likelihood of crystal formation. Unused autoclaved ampules should be discarded. Under no circumstances should unused ampules which have been autoclaved be returned to stock.</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s19"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">1% isotonic isobaric solution: 2 mL Ampules, box of 25.
</p>
<p>NDC 17478-045-32
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s20"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store under refrigeration. Protect ampules from light.
</p>
<p>Akorn<br>Manufactured by: Akorn, Inc.<br>Lake Forest, IL 60045
</p>
<p>GTC00N <br>Rev. 12/08
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s21"></a><a name="section-11"></a><p></p>
<h1>Principal Display Panel Text for Container Label:
</h1>
<p class="First">NDC 17478-045-32
</p>
<p>TETRACAINE 1%
</p>
<p>Tetracaine HCl Injection, USP
</p>
<p>10 mg/mL
</p>
<p>2 mL Ampule
</p>
<p>PRESERVATIVE-FREE
</p>
<p>Akorn logo                 Rx only
</p>
<p>Mfg. by: Akorn, Inc.
</p>
<p>Lake Forest, IL 60045     GTCADL Rev. 12/08
</p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel Text for Container Label:
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b29124f7-c238-4961-b810-f4e7fabe4bb1&amp;name=tetracaine-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s22"></a><a name="section-12"></a><p></p>
<h1>Principal Display Panel Text for Carton Label:
</h1>
<p class="First">NDC 17478-045-32
</p>
<p>TETRACAINE 1%
</p>
<p>Tetracaine HCl Injection, USP
</p>
<p>For Prolonged Spinal Anesthesia
</p>
<p>PRESERVATIVE-FREE
</p>
<p>PROTECT FROM LIGHT. STORE UNDER REFRIGERATION
</p>
<p>10 mg/mL
</p>
<p>25 Ampules (2 mL each)
</p>
<p>Rx only              [Akorn Logo]
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel Text for Carton Label:
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b29124f7-c238-4961-b810-f4e7fabe4bb1&amp;name=tetracaine-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TETRACAINE 		
					</strong><br><span class="contentTableReg">tetracaine hcl injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-045</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBARACHNOID</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tetracaine hydrochloride</strong> (tetracaine) </td>
<td class="formItem">tetracaine hydrochloride</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-045-32</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">06/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn, Inc.
							(062649876)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Akorn, Inc.</td>
<td class="formItem"></td>
<td class="formItem">155135783</td>
<td class="formItem">MANUFACTURE, ANALYSIS, PACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ee2a9b04-7c88-4c8d-8a55-d8ca73e03b59</div>
<div>Set id: b29124f7-c238-4961-b810-f4e7fabe4bb1</div>
<div>Version: 1</div>
<div>Effective Time: 20100414</div>
</div>
</div> <div class="DistributorName">Akorn, Inc.</div></p>
</body></html>
